Literature DB >> 21436353

Pseudomonas aeruginosa induces vascular endothelial growth factor synthesis in airway epithelium in vitro and in vivo.

C Martin1, G Thévenot, S Danel, J Chapron, A Tazi, J Macey, D J Dusser, I Fajac, P-R Burgel.   

Abstract

Pseudomonas aeruginosa (PA) airway infection and bronchial blood vessel proliferation are features of bronchiectasis. Because vascular endothelial growth factor (VEGF)-A regulates angiogenesis, we hypothesised that PA infection induces VEGF synthesis in epithelium and peribronchial angiogenesis. Because epidermal growth factor receptor (EGFR) activation regulates VEGF synthesis in cancer, we also evaluated the roles of EGFR. Airway epithelial cells were incubated for 24 h with PA supernatants and VEGF concentrations were measured in culture medium by ELISA. C57BL/6N mice were instilled intratracheally with sterile agarose beads or with agarose beads coated with the PA strain PAO1 (mean ± sem 6 × 10(5) ± 3 × 10(5) cfu · animal(-1)), with or without the EGFR inhibitor AG1478 (12.5 mg · kg(-1) · day(-1) intraperitoneally). Epithelial immunostaining for VEGF and phosphorylated EGFR, and peribronchial vascularity, were quantified using morphometric analysis. VEGF expression was further assessed by western blot in mouse lung homogenates. PA supernatants induced dose-dependent VEGF synthesis in cultured airway epithelial cells, effects which were prevented by EGFR antagonists. In mice, persistent PAO1 infection increased immunostaining for VEGF and phosphorylated EGFR in airway epithelium, and resulted in increased peribronchial vascularity within 7 days. These effects were reduced by EGFR inhibition. Persistent PA infection induced VEGF synthesis in airway epithelium and peribronchial angiogenesis, at least in part via EGFR-dependent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436353     DOI: 10.1183/09031936.00134910

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  An inactivated Pseudomonas aeruginosa medicament inhibits airway allergic inflammation and improves epithelial functions.

Authors:  Yurong Tan; Huijun Liu; Huihui Yang; Lili Wang; Xiaoqun Qin
Journal:  J Physiol Sci       Date:  2012-09-26       Impact factor: 2.781

2.  Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Authors:  Shailendra R Singh; Nikol Sullo; Maria Matteis; Giuseppe Spaziano; John McDonald; Ruth Saunders; Lucy Woodman; Konrad Urbanek; Antonella De Angelis; Raffaele De Palma; Rachid Berair; Mitesh Pancholi; Vijay Mistry; Francesco Rossi; Remo Guerrini; Girolamo Calò; Bruno D'Agostino; Christopher E Brightling; David G Lambert
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

3.  Pseudomonas aeruginosa biofilm hampers murine central wound healing by suppression of vascular epithelial growth factor.

Authors:  Hannah Trøstrup; Christian J Lerche; Lars J Christophersen; Kim Thomsen; Peter Ø Jensen; Hans Petter Hougen; Niels Høiby; Claus Moser
Journal:  Int Wound J       Date:  2017-11-27       Impact factor: 3.315

4.  Membrane-tethered MUC1 mucin is phosphorylated by epidermal growth factor receptor in airway epithelial cells and associates with TLR5 to inhibit recruitment of MyD88.

Authors:  Kosuke Kato; Erik P Lillehoj; Yong Sung Park; Tsuyoshi Umehara; Nicholas E Hoffman; Muniswamy Madesh; K Chul Kim
Journal:  J Immunol       Date:  2012-01-16       Impact factor: 5.422

Review 5.  Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa.

Authors:  Aurélie Crabbé; Maria A Ledesma; Cheryl A Nickerson
Journal:  Pathog Dis       Date:  2014-05-23       Impact factor: 3.166

6.  Infectious diseases are analogous with cancer. Hypothesis and implications.

Authors:  Daniel Benharroch; Lidia Osyntsov
Journal:  J Cancer       Date:  2012-03-06       Impact factor: 4.207

7.  Reply to Polverino: Deconvoluting Chronic Obstructive Pulmonary Disease: Are B Cells the Frontrunners?

Authors:  Maha Zohra Ladjemi; Pierre Régis Burgel; Charles Pilette
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

Review 8.  The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-10-27       Impact factor: 2.849

9.  Prevalence and burden of bronchiectasis in a lung cancer screening program.

Authors:  Maria Sanchez-Carpintero Abad; Pablo Sanchez-Salcedo; Juan P de-Torres; Ana B Alcaide; Luis M Seijo; Jesus Pueyo; Gorka Bastarrika; Javier J Zulueta; Arantza Campo
Journal:  PLoS One       Date:  2020-04-13       Impact factor: 3.240

10.  Differences in airway microbiome and metabolome of single lung transplant recipients.

Authors:  Nirmal S Sharma; Grant Vestal; Keith Wille; Kapil N Patel; Feng Cheng; Srinivas Tipparaju; Sultan Tousif; Mudassir M Banday; Xin Xu; Landon Wilson; Viswam S Nair; Casey Morrow; Don Hayes; Andreas Seyfang; Stephen Barnes; Jessy S Deshane; Amit Gaggar
Journal:  Respir Res       Date:  2020-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.